Dr. Hafez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
11800 Wilshire Blvd
Los Angeles, CA 90025Phone+1 310-231-2121Fax+1 310-564-1735- Is this information wrong?
Summary
- Dr. Navid Hafez is an oncologist in Los Angeles, CA and is affiliated with The Angeles Clinic and Research Institute and Cedars-Sinai. He received his medical degree from University of Wisconsin School of Medicine and Public Health and completed his internal medicine residency and hematology/oncology fellowship at Yale University. He specializes in breast cancer, thoracic cancer, and early drug development and is experienced in phase 1 clinical research. He has more than 10 publications and over 500 citings.
Education & Training
- Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
- Yale-New Haven Medical CenterResidency, Internal Medicine, 2010 - 2013
- University of Wisconsin School of Medicine & Public HealthClass of 2010
Certifications & Licensure
- CA State Medical License 2023 - 2025
- CT State Medical License 2016 - 2023
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) Start of enrollment: 2019 Jun 11
- A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2019 Dec 12
Roles: Principal Investigator
Publications & Presentations
PubMed
- A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.Gerald Falchook, Amita Patnaik, Debra L Richardson, R Donald Harvey, Manish R Sharma, Navid Hafez, Erika Hamilton, Sarina A Piha-Paul, Minal Barve, Trisha Wise-Draper,...> ;Clinical Therapeutics. 2024 Mar 1
- Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.Noboru Yamamoto, Iwona Lugowska, Rodryg Ramlau, Teresa Macarulla, Junxian Geng, Jian Li, Michael Teufel, Angela Märten, Anthony Tolcher, Navid Hafez, Patricia LoRusso> ;Oncotargets and Therapy. 2024 Jan 1
- NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph P Eder, Kurt A Schalper, Alice P Chen, Patricia LoRusso> ;Cancer Research Communications. 2023 Jun 1
- Join now to see all
Hospital Affiliations
- Yale-New Haven HospitalNew Haven, Connecticut
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: